9 results on '"Anovulation diagnosis"'
Search Results
2. The 28th-day myth
- Author
-
Yeager, Selene
- Subjects
Menstruation disorders -- Diagnosis ,Menstruation disorders -- Care and treatment ,Anovulation -- Diagnosis ,Anovulation -- Care and treatment ,General interest ,Women's issues/gender studies - Abstract
Only 28% of women in a study had textbook cycles, or regular 28-day periods. Perimenopausal women's menstrual cycles can exceed 35 days, while women who miss periods entirely may be experiencing anovulation. Menstruation issues such as heavy flows and more painful periods, the reasons behind symptoms, and the corresponding solutions, are given.
- Published
- 2008
3. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders.
- Author
-
Vagios, Stylianos, James, Kaitlyn E., Sacha, Caitlin R., Hsu, Jennifer Y., Dimitriadis, Irene, Bormann, Charles L., and Souter, Irene
- Subjects
- *
ANOVULATION , *ANTI-Mullerian hormone , *POLYCYSTIC ovary syndrome , *BODY mass index , *RECEIVER operating characteristic curves , *INDUCED ovulation , *PROGNOSIS , *INDIVIDUALITY , *RETROSPECTIVE studies , *DIFFERENTIAL diagnosis , *INFERTILITY , *OVARIAN reserve , *SEX hormones , *LOGISTIC regression analysis , *DISEASE complications - Abstract
Objective: To determine whether a patient-specific predictive model combining antimüllerian hormone (AMH) levels and body mass index (BMI) can aid in the diagnosis of polycystic ovary syndrome (PCOS) and other ovulatory dysfunction disorders (OVDYS) among infertile women.Design: Retrospective cohort study.Setting: Academic fertility center.Patient(s): One thousand and ten infertile women undergoing 3,160 intrauterine insemination (IUI) cycles, stratified by diagnosis in three groups: PCOS, OVDYS, and other etiologies.Intervention(s): Ovulation induction followed by IUI or ultrasound-monitored natural cycles.Main Outcome Measure(s): The probability of either PCOS or OVDYS diagnosis based on AMH levels alone and a patient-specific predictive model that combines serum AMH and patient's BMI.Result(s): Median and interquartile range (IQR) for the serum AMH levels (ng/mL) were the highest in women with PCOS, and lowest in those with other infertility causes. Overall, for every 1 ng/mL increase in AMH, the odds of PCOS and OVDYS versus other causes increased by 55% and 24%, respectively. Postestimation from multivariate logistic regression models showed that PCOS diagnosis can be predicted with lower AMH values in women with a higher BMI compared with the AMH values predicting PCOS in normal-weight or underweight patients. The receiver operating characteristic curves reinforced these findings, and the best cutoffs for PCOS diagnosis were 7.5, 4.4, and 4.1 ng/mL for women belonging to the BMI groups 18.5-24.9, 25.0-29.9, and ≥30.0 kg/m2, respectively.Conclusion(s): Taking into account AMH and BMI, we developed a model that predicts the probability of an oligo-anovulation diagnosis, thus facilitating patient-specific counseling in the infertility setting. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Progress of the application clinical prediction model in polycystic ovary syndrome.
- Author
-
Guixue, Guan, Yifu, Pu, Yuan, Gao, Xialei, Liu, Fan, Shi, Qian, Sun, Jinjin, Xu, Linna, Zhang, Xiaozuo, Zhang, Wen, Feng, and Wen, Yang
- Subjects
POLYCYSTIC ovary syndrome ,PREDICTION models ,CLINICAL medicine ,INDUCED ovulation ,MEDICAL research personnel ,DISEASE incidence - Abstract
Clinical prediction models play an important role in the field of medicine. These can help predict the probability of an individual suffering from disease, complications, and treatment outcomes by applying specific methodologies. Polycystic ovary syndrome (PCOS) is a common disease with a high incidence rate, huge heterogeneity, short- and long-term complications, and complex treatments. In this systematic review study, we reviewed the progress of clinical prediction models in PCOS patients, including diagnosis and prediction models for PCOS complications and treatment outcomes. We aimed to provide ideas for medical researchers and clues for the management of PCOS. In the future, models with poor accuracy can be greatly improved by adding well-known parameters and validations, which will further expand our understanding of PCOS in terms of precision medicine. By developing a series of predictive models, we can make the definition of PCOS more accurate, which can improve the diagnosis of PCOS and reduce the likelihood of false positives and false negatives. It will also help discover complications earlier and treatment outcomes being known earlier, which can result in better outcomes for women with PCOS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. A 34-Year-Old Woman with a Diamniotic Dichorionic Twin Pregnancy Presenting with an Erythematous and Papular Skin Rash Associated with SARS-CoV-2 Infection.
- Author
-
Oropeza Chávez, Liliana, Sánchez Tinajero, Ángel, Martínez Orozco, José Arturo, Becerril Vargas, Eduardo, De la Merced, Alfredo Dolores, Ruiz Santillán, Danna Patricia, Delgado Cueva, Andrea Iraís, and Alvarado Peña, Nestor
- Subjects
COVID-19 ,SARS-CoV-2 ,PREGNANT women ,PREGNANCY ,PATHOLOGY - Abstract
Objective: Rare co-existance of disease or pathology Background: The damage caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has been extensive. Pregnant women are a group requiring special attention in medicine given the anatomical and physiological changes that occur during pregnancy. Skin rash is commonly associated with pregnancy, with the most common form of an erythematous maculopapular rash being pruritic urticarial papules and plaques of pregnancy. Skin rash is also an increasingly reported initial presentation in patients with coronavirus disease 2019 (COVID-19), due to infection with SARS-CoV-2. Case Report: A 34-year-old woman with a diamniotic dichorionic twin pregnancy presented with clinical picture characterized by dermatological manifestations, namely an erythematous and papular skin rash associated with SARSCoV-2 infection. A real-time reverse transcription-polymerase chain reaction (GeneFinder) test was positive for SARS-CoV-2 detection. Conclusions: Ten months after the onset of this pandemic, there is no conclusive evidence indicating that pregnant women represent a sector more or less vulnerable to severe forms of COVID-19 than the general population. This report has highlighted the importance of performing a reliable diagnostic test for SARS-CoV-2 infection in patients who present with a skin rash, particularly pregnant women. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Impact of trophectoderm biopsy on obstetric and perinatal outcomes following frozen-thawed embryo transfer cycles.
- Author
-
Makhijani, Reeva, Bartels, Chantal Barbara, Godiwala, Prachi, Bartolucci, Alison, DiLuigi, Andrea, Nulsen, John, Grow, Daniel, Benadiva, Claudio, and Engmann, Lawrence
- Subjects
EMBRYO transfer ,FERTILIZATION in vitro ,FETAL growth retardation ,PLACENTA accreta ,FROZEN tissue sections ,BIOPSY ,CELL analysis ,BLASTOCYST ,RESEARCH ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RANDOMIZED controlled trials ,LONGITUDINAL method - Abstract
Study Question: Does trophectoderm biopsy for preimplantation genetic testing (PGT) increase the risk of obstetric or perinatal complications in frozen-thawed embryo transfer (FET) cycles?Summary Answer: Trophectoderm biopsy may increase the risk of hypertensive disorders of pregnancy (HDP) in pregnancies following FET cycles.What Is Known Already: Trophectoderm biopsy has replaced blastomere biopsy as the standard of care to procure cells for PGT analysis. Recently, there has been concern that trophectoderm biopsy may adversely impact obstetric and perinatal outcomes. Previous studies examining this question are limited by use of inappropriate control groups, small sample size or reporting on data that no longer reflects current IVF practice.Study Design, Size, Duration: This was a retrospective cohort study conducted at a single university-affiliated fertility center. A total of 756 patients who underwent FET with transfer of previously vitrified blastocysts that had either trophectoderm biopsy or were unbiopsied and resulted in a singleton live birth between 2013 and 2019 were included.Participants/materials, Setting, Methods: Obstetric and perinatal outcomes for patients aged 20-44 years who underwent FET with transfer of previously vitrified blastocysts that were either biopsied (n = 241) or unbiopsied (n = 515) were analyzed. Primary outcome was odds of placentation disorders including HDP and rate of fetal growth restriction (FGR). Binary logistic regression was performed to control for potential covariates.Main Results and the Role Of Chance: The biopsy group was significantly older, had fewer anovulatory patients, was more often nulliparous and had fewer embryos transferred compared to the unbiopsied group. After controlling for potential covariates, the probability of developing HDP was significantly higher in the biopsy group compared with unbiopsied group (adjusted odds ratio (aOR) 1.943, 95% CI 1.072-3.521; P = 0.029).There was no significant difference between groups in the probability of placenta previa or placenta accreta. There was also no significant difference in the rate of FGR (aOR 1.397; 95% CI, 0.815-2.395; P = 0.224) or the proportion of low (aOR 0.603; 95% CI, 0.336-1.084; P = 0.091) or very low (aOR 2.948; 95% CI, 0.613-14.177; P = 0.177) birthweight infants comparing biopsied to unbiopsied groups.Limitations, Reason For Caution: This was a retrospective study performed at a single fertility center, which may limit the generalizability of our findings.Wider Implications Of the Findings: Trophectoderm biopsy may increase the risk of HDP in FET cycles, however, a prospective multicenter randomized trial should be performed to confirm these findings.Study Funding/competing Interest(s): No specific funding was obtained for this study. The authors declare no conflict of interest.Trial Registration Number: NA. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders
- Author
-
Kaitlyn E. James, Charles L. Bormann, Jennifer Y. Hsu, Irene Souter, Caitlin R. Sacha, Irene Dimitriadis, and Stylianos Vagios
- Subjects
Infertility ,Adult ,Anti-Mullerian Hormone ,medicine.medical_specialty ,endocrine system diseases ,medicine.medical_treatment ,Individuality ,Body Mass Index ,Anovulation ,Diagnosis, Differential ,Interquartile range ,medicine ,Humans ,Precision Medicine ,Ovarian Reserve ,Diagnostic Techniques, Obstetrical and Gynecological ,Retrospective Studies ,business.industry ,Obstetrics ,nutritional and metabolic diseases ,Obstetrics and Gynecology ,Retrospective cohort study ,medicine.disease ,Prognosis ,Polycystic ovary ,female genital diseases and pregnancy complications ,Logistic Models ,Reproductive Medicine ,Ovulation induction ,Female ,Underweight ,medicine.symptom ,business ,Body mass index ,Infertility, Female ,Polycystic Ovary Syndrome - Abstract
Objective To determine whether a patient-specific predictive model combining antimullerian hormone (AMH) levels and body mass index (BMI) can aid in the diagnosis of polycystic ovary syndrome (PCOS) and other ovulatory dysfunction disorders (OVDYS) among infertile women. Design Retrospective cohort study. Setting Academic fertility center. Patient(s) One thousand and ten infertile women undergoing 3,160 intrauterine insemination (IUI) cycles, stratified by diagnosis in three groups: PCOS, OVDYS, and other etiologies. Intervention(s) Ovulation induction followed by IUI or ultrasound-monitored natural cycles. Main Outcome Measure(s) The probability of either PCOS or OVDYS diagnosis based on AMH levels alone and a patient-specific predictive model that combines serum AMH and patient’s BMI. Result(s) Median and interquartile range (IQR) for the serum AMH levels (ng/mL) were the highest in women with PCOS, and lowest in those with other infertility causes. Overall, for every 1 ng/mL increase in AMH, the odds of PCOS and OVDYS versus other causes increased by 55% and 24%, respectively. Postestimation from multivariate logistic regression models showed that PCOS diagnosis can be predicted with lower AMH values in women with a higher BMI compared with the AMH values predicting PCOS in normal-weight or underweight patients. The receiver operating characteristic curves reinforced these findings, and the best cutoffs for PCOS diagnosis were 7.5, 4.4, and 4.1 ng/mL for women belonging to the BMI groups 18.5–24.9, 25.0–29.9, and ≥30.0 kg/m2, respectively. Conclusion(s) Taking into account AMH and BMI, we developed a model that predicts the probability of an oligo-anovulation diagnosis, thus facilitating patient-specific counseling in the infertility setting.
- Published
- 2020
8. Management of anovulatory infertility.
- Author
-
Crosignani, P.G., Bianchedi, D., Riccaboni, A., and Vegetti, W.
- Abstract
Chronic anovulation is probably the major cause of human infertility and is essentially associated with four distinct endocrine conditions; hyperprolactinemic anovulation, hypogonadotrophic anovulation, normogonadotrophic anovulation and hypergonadotrophic anovulation. Hyperprolactinaemia and microprolactinoma are frequent findings in young women and excessive prolactin secretion impairs ovarian function causing anovulatory subfertility. Dopaminergic treatment restores ovarian function and shrinks prolacinoma. In these patients restoration of fertility with prolactin lowering drugs does not increase the incidence of multiple pregnancies or early pregnancy loss. In the vast majority of hyperprolactinemic women pregnancy is safe and could be beneficial. Cabergoline is the most effective and tolerated of the antiprolactinemic drugs. Hypogonadotrophic anovulation is frequently associated with acute or chronic emotional stress and in this case the patient should be counselled. Explanation and reassurance are the first important management steps. The use of pulsatile gonadotrophin-releasing hormone is the best strategy to induce fertility. Patients with normogonadotrophic anovulation are likely to have polycystic ovary. The most cost effective profertility treatment is the administration of an anti-oestrogen such as clomiphene or tamoxifen. The second choice therapy for patients with normogonadotrophic anovulation is ovarian stimulation with human gonadotrophin preparations. Low dose modifications give pregnancy rates lower than that with the traditional high-dose step-up protocol and intensive monitoring is required, but multiple pregnancies are less frequent. No treatment is available to enable women with hypergonadotrophic anovulation to conceive. Fertility in these patients can be promoted only by an egg donation programme. [ABSTRACT FROM PUBLISHER]
- Published
- 1999
- Full Text
- View/download PDF
9. Data on Polycystic Ovary Syndrome Discussed by Researchers at Massachusetts General Hospital (A Patient-specific Model Combining Antimullerian Hormone and Body Mass Index As a Predictor of Polycystic Ovary Syndrome and Other Oligo-anovulation ...)
- Subjects
Women -- Health aspects ,Medical research -- Analysis -- Reports ,Medicine, Experimental -- Analysis -- Reports ,Stein-Leventhal syndrome -- Research ,Hormones -- Research -- Reports -- Analysis ,Body mass index -- Reports -- Research -- Analysis ,Health ,Women's issues/gender studies ,Massachusetts General Hospital -- Reports - Abstract
2021 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Endocrine System Diseases and Conditions - Polycystic Ovary Syndrome. [...]
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.